Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- American Lung AssociationChronic Lung Disease Advocates From Across Nation Head to Capitol Hill to Champion Lung HealthAmerican Lung Association to host 4th Respiratory Advocacy Day in Washington, D.C., on September 24 — On September 24, the American Lung Association will host its fourth Respiratory Advocacy Day, bringing people living with a chronic lung disease from...
- HepaRegeniX Completes Darizmetinib Treatment Phase for First Patient Undergoing Major Liver Resection in Phase 1b Liver Regeneration StudyFirst patient completed the 28 day treatment with darizmetinib. Second Ph1b pilot part of study expected to enroll 10 patients and be completed by Q4 2026.
- Cleanroom Lighting Market 2026: Pharma, Biotech and Semiconductor Expansion Fuels New Growth OpportunitiesLED upgrades, smart IoT controls and recessed fixtures offer opportunities as pharma, biotech and chipmaking expand cleanrooms, led by Asia-Pacific and stricter compliance.
- Opterion Health Announces Positive Phase 1 Results for OPT101, Supporting Advancement to Phase 2aOpterion Health reports positive Phase 1 OPT101 results, supporting Phase 2a and advancing a differentiated non-glucose approach to peritoneal dialysis.
- China Medical University HospitalChina Medical University Hospital Named to Newsweek's World's Best Specialized Hospitals 2027 for NeurosurgeryCMUH is the only hospital in Taiwan recognized in the Neurosurgery category, reflecting its strengths in complex neurosurgery, integrated neurological care and cell therapy — China Medical University Hospital (CMUH) has been named to Newsweek's...
- [Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesityCompanies: Roche HoldingBasel, 22 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) today announced positive topline results from CT-388-104, a Phase II clinical trial evaluating enicepatide (CT-388), an investigational, once-weekly dual GLP-1/GIP receptor agonist, in adults living with type 2 diabetes (T2D) and overweight or obesity. In the study, enicepatide met both primary endpoints, delivering dose-dependent and clinically meaningful reductions in blood glucose and body weight at 48 weeks. Patients receiving the highest titrated dose (24 mg) achieved an HbA1c reduction of 2.65% (from a baseline HbA1c of 8.1%). Furthermore, 90% of patients in the 24 mg cohort reached an HbA1c level of ≤6.5% (diagnostic threshold for T2D) and 62% achieved normoglycemia (HbA1c < 5.7%), restoring blood glucose levels to a non-diabetic range. The mean weight loss at 48 weeks in the 24 mg enicepatide arm was 15.5% without a demonstrable plateau.
- BestzymeBestzyme Launches World's First Dedicated, Automated Smart Production Line for Sweet Proteins in JinanBestzyme, a synthetic biology company under GenScript Biotech, today announced the completion of the world's first dedicated, automated smart production line for sweet proteins at its Jinan facility. This milestone marks the first full-chain...
- Respiree Pte Ltd HOUSTON andRespiree Extends Series A Syndicate with Addition of International Investors to Support Continued Global GrowthRespiree, a health tech company developing artificial intelligence (AI) platforms to manage disease progression across the healthcare continuum, today announced that ARKRAY & PARTNERS Pte. Ltd. (AAP) and Bizedge Capital have joined its Series A syndicate.
- Akeso, Inc.Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that nearly 30 clinical studies of its globally first-in-class bispecific antibodies will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place...
- Merry Life BiomedicalMerry Life Biomedical Advances Global Phase 2 Trial of TML-6, Exploring Cellular Protein Clearance in Early Alzheimer's DiseaseGlobal study brings together nine Taiwan medical centers, seven Swedish sites, and four U.S. centers to evaluate an oral therapy focused on autolysosomal biology — Merry Life Biomedical today announced the advancement of TML-6, a Taiwan-developed...
- His Choice Health RichmondHis Choice Health Opens Richmond Vasectomy Clinic, Bringing Single-Visit Care to VirginiaNew Richmond location expands access to minimally invasive no-scalpel vasectomy with transparent pricing, single-visit scheduling and mail-in follow-up testing.
- The Rosen Law Firm PAROSEN, HIGHLY REGARDED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - HIMSWHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead plaintiff deadline.SO WHAT: If you purchased Hims securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement....